JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon Pharmaceuticals to $54 from $52 and keeps an Overweight rating on the shares. The analyst introduced a potassium channel activator market model for the adjunctive treatment of focal onset seizures. She projects 15%-17% Kv7 activator penetration within the treatment-resistant FOS market with "plenty of room for multiple players with differentiated efficacy and tolerability profiles."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on XENE:
- Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Xenon Pharmaceuticals initiated with a Buy at Goldman Sachs
- Xenon Pharmaceuticals initiated with an Outperform at Cowen on XEN1101 optimism
- Xenon Pharmaceuticals initiated with an Outperform at Cowen
- Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
